<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2817">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04463628</url>
  </required_header>
  <id_info>
    <org_study_id>MUCONFIN</org_study_id>
    <nct_id>NCT04463628</nct_id>
  </id_info>
  <brief_title>Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic</brief_title>
  <acronym>MUCONFIN</acronym>
  <official_title>Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Impacts of the Covid-19 epidemic and associated lockdown measures on the management, health
      and behaviors of cystic fibrosis patients during the 2020 epidemic
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The containment of the population in France is a health measure implemented in response to
      SARS-CoV-2 (Covid-19) infection. For cystic fibrosis, as for many chronic diseases, this
      disruption is twofold. On the one hand, it affects daily life due to the closure of schools
      and the introduction of national lockdown, but also the hospital, which has profoundly
      changed its procedures, which are almost completely focused on the care of patients with
      Covid-19. This forced transformation was at the expense of its usual role including the
      management of chronic diseases such as cystic fibrosis. It has an impact on patients'
      consultations cancelled, rescheduled or replaced by teleconsultations, hospitalisations
      whether scheduled or during acute exacerbations which are more complicated to organise.
      Access to treatments is also more difficult (physiotherapy), which can affect compliance.
      Confinement also profoundly changes the lives of our patients. It changes the way individuals
      can apprehend their disease and its integration into their everyday life, studies or
      professional projects. Finally, it is the confrontation with a potentially fatal infection
      that reminds us of the risks and consequences of a potentially severe chronic disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cancellation or postponement of consultations by the health professional or patient,</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of consultations cancelled or postponed by the health professional or patient of consultations (medical and paramedical),</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient cancellation of teleconsultations/telecare replacement,</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of consultations cancelled by the teleconsultation/replacement patient,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cancellation or postponement by the health care institution or by the patient of hospitalizations (scheduled or unscheduled),</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of consultations cancelled or postponed by the health care institution or by the patient of hospitalizations (acute or scheduled)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the modalities of administration of antibiotics cures (oral instead of intravenous administration).</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of patients affected by the change in the modality of administration of antibiotic cures (intravenous instead of intravenous administration).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The reduction of each of the elements of care provision and health care utilization:</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Cancellation or postponement by the patient of consultations (medical or paramedical)
Patient cancellation of teleconsultations/telecare proposed by the health professional
Cancellation or postponement by the patient of hospitalizations (acute or scheduled)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of modality of administration of antibiotic cures</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Intravenous instead of intravenous administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Questionnaire about taking or not taking treatment during confinement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and stress (at risk of being affected by COVID-19 or at risk of being treated less well)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Scale 0-21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of toxic consumption (drug, alcohol) during the lockdown</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>A questionnaire on the presence or absence of toxic consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the knowledge, experience and social representations of the risk of Covid-19</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Experience and social representations of confinement by cystic fibrosis patients (evaluated by qualitative methods)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing the role of social inequalities in the consequences of lockdown</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Role of social inequalities in the consequences of containment assessed by qualitative methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suspected and/or confirmed Covid-19 in patients with cystic fibrosis.</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Prevalence of suspected and/or confirmed Covid-19 infections in patients with cystic fibrosis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Cystic Fibrosis in Children</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Questionnaire and/or interview</arm_group_label>
    <description>An online questionnaire to assess the quantitative aspect of the impact of lockdown on all areas of the cystic fibrosis patient's health, be it physical, mental or social (using quality of life assessment in particular and interviews in the human and social sciences).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>The study questionnaire was constructed as follows:
One part is composed of validated questionnaires: Cystic fibrosis specific self-questionnaire for quality of life, questionnaire for screening for anxiety disorder.
The other part, which was not validated, was constructed as follows: questionnaire on knowledge of Covid-19 adapted to the new exceptional situation (Covid-19 pandemic) and specific questions adapted to the research objective on Covid-19 from the questionnaire of the French Public Health survey, to monitor changes in behaviour and mental health during lockdown</description>
    <arm_group_label>Questionnaire and/or interview</arm_group_label>
    <other_name>Quantitative aspect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Interview</intervention_name>
    <description>Two interviews in the human and social sciences, conducted by recorded video-conference, will be proposed to 15 patients during and after the lockdown.Two interviews will take place: one during the lockdown and one at 6 months from the first interview (or at the end of the confinement if it lasts more than 6 months). The interviews will be conducted independently of the results of the questionnaire.</description>
    <arm_group_label>Questionnaire and/or interview</arm_group_label>
    <other_name>Qualitative aspect</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will be proposed to cystic fibrosis patients residing in France.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with cystic fibrosis (Southern Chlorine &gt; 60 mEq/L and/or presence of 2
             pathogenic mutations on the CFTR gene)

          -  Supported in a French CRCM (Cystic fibrosis Resource and Competence Center)

          -  Affiliated to a social security scheme

          -  Non-opposition for participation in the protocol

        Exclusion Criteria:

          -  Minor patient under 14 years of age

          -  Computer equipment or internet connection defect
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ralph EPAUD, MD, PhD</last_name>
    <phone>01 45 17 54 19</phone>
    <phone_ext>+33</phone_ext>
    <email>ralph.epaud@chicreteil.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Intercommunal hospital of Cr√©teil</name>
      <address>
        <city>Creteil</city>
        <state>IDF</state>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph EPAUD, MD PhD</last_name>
      <phone>01.45.17.54.19</phone>
      <phone_ext>+33</phone_ext>
      <email>ralph.epaud@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Ralph EPAUD, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TROUSSEAU Hospital</name>
      <address>
        <city>Paris</city>
        <state>IDF</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harriet CORVOL, MD, PhD</last_name>
      <phone>01.44.73.66.68</phone>
      <email>harriet.corvol@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FOCH Hospital</name>
      <address>
        <city>Suresnes</city>
        <state>IDF</state>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique GRENET, MD, PhD</last_name>
      <phone>01 46 25 25 82</phone>
      <phone_ext>+33</phone_ext>
      <email>d.grenet@hopital-foch.org</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lockdown</keyword>
  <keyword>Covid-19 Epidemic</keyword>
  <keyword>questionnaire</keyword>
  <keyword>interview</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

